Abstract
Over the past few decades significant advances have been made in the development of nanopharmaceuticals (including phospholipid and polymer-based therapeutics) against cancer. There is still, however, room for improvement. Today, many researchers are focusing on the development of innovative approaches to selectively deliver drugs to solid tumors, while minimizing insult to healthy tissues. Unfortunately, the majority of these efforts are confronted by physiological barriers that reduce the clinical dose required to effectively manage the disease state. In an effort to develop promising nanopharmaceutical products of the future, we review the most important problems facing drug delivery experts today. We discuss here, the physiological role of solid tumors in delivery and transport of nanopharmaceutical products. The nature of tumors in terms of their unique anatomical structure and functions is also discussed. Finally, an overview of ways to overcome physiological barrier functions and exploit tumor pathogenesis for therapeutic gain is provided.
Keywords: Tumor vasculature, interstitial transport, vascular permeability, interstitial fluid pressure
Anti-Cancer Agents in Medicinal Chemistry
Title: Tumor Physiology and Delivery of Nanopharmaceuticals
Volume: 6 Issue: 6
Author(s): Robert B. Campbell
Affiliation:
Keywords: Tumor vasculature, interstitial transport, vascular permeability, interstitial fluid pressure
Abstract: Over the past few decades significant advances have been made in the development of nanopharmaceuticals (including phospholipid and polymer-based therapeutics) against cancer. There is still, however, room for improvement. Today, many researchers are focusing on the development of innovative approaches to selectively deliver drugs to solid tumors, while minimizing insult to healthy tissues. Unfortunately, the majority of these efforts are confronted by physiological barriers that reduce the clinical dose required to effectively manage the disease state. In an effort to develop promising nanopharmaceutical products of the future, we review the most important problems facing drug delivery experts today. We discuss here, the physiological role of solid tumors in delivery and transport of nanopharmaceutical products. The nature of tumors in terms of their unique anatomical structure and functions is also discussed. Finally, an overview of ways to overcome physiological barrier functions and exploit tumor pathogenesis for therapeutic gain is provided.
Export Options
About this article
Cite this article as:
Campbell B. Robert, Tumor Physiology and Delivery of Nanopharmaceuticals, Anti-Cancer Agents in Medicinal Chemistry 2006; 6 (6) . https://dx.doi.org/10.2174/187152006778699077
DOI https://dx.doi.org/10.2174/187152006778699077 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Development of Pro-Apoptotic Cancer Therapeutics
Mini-Reviews in Medicinal Chemistry A Computational Study of Three Frequent Mutations of EGFR and their Effects on Protein Dimer Formation and Non-Small Cell Lung Cancer Drug Resistance
Current Bioinformatics Recognition of Invasive Prostate Cancer Using a GHRL Polypeptide Probe Targeting GHSR in a Mouse Model <I>In Vivo</I>
Current Pharmaceutical Design Computational Approaches for Predicting Causal Missense Mutations in Cancer Genome Projects
Current Bioinformatics Resveratrol in Medicinal Chemistry: A Critical Review of its Pharmacokinetics, Drug-Delivery, and Membrane Interactions
Current Medicinal Chemistry Taxanes: Microtubule and Centrosome Targets, and Cell Cycle Dependent Mechanisms of Action
Current Cancer Drug Targets Structure-based Design of Conformationally Flexible Reverse Transcriptase Inhibitors to Combat Resistant HIV
Current Pharmaceutical Design Recent Advances in the Chemistry and Biology of Folypoly-γ-glutamate Synthetase Substrates and Inhibitors
Current Medicinal Chemistry - Anti-Cancer Agents Tumor Angiogenesis: A Potential Target In Cancer Control by Phytochemicals
Current Cancer Drug Targets Clinicopathological Characteristics of Chinese Colorectal Cancer Patients under 30 Years of Age: Implication in Diagnosis and Therapy
Current Cancer Drug Targets Biomedical Applications of Poly(Lactic Acid)
Recent Patents on Regenerative Medicine The Use of Synthetic Oligonucleotides as Protein Inhibitors and Anticode Drugs in Cancer Therapy: Accomplishments and Limitations
Current Cancer Drug Targets Hsp90: A Novel Target for the Disruption of Multiple Signaling Cascades
Current Cancer Drug Targets Influence of Labelling Methods on Biodistribution and Imaging Properties of Radiolabelled Peptides for Visualisation of Molecular Therapeutic Targets
Current Medicinal Chemistry T Cell Costimulatory and Inhibitory Receptors as Therapeutic Targets for Inducing Anti-Tumor Immunity
Current Cancer Drug Targets Short-Chain Fatty Acid Inhibitors of Histone Deacetylases: Promising Anticancer Therapeutics?
Current Cancer Drug Targets Modulation of the Endocannabinoid System by Lipid Rafts
Current Medicinal Chemistry The Problem of False-Positive Human Papillomavirus DNA Tests in Cervical Screening
Current Pharmaceutical Design Synthesis and Antitumor Activity of 2-Aryl-1, 2, 4-Triazolo[1, 5-a] Pyridine Derivatives
Medicinal Chemistry Shaping the Genome with Non-Coding RNAs
Current Genomics